Department of Nuclear Medicine, Soonchunhyang University Hospital, Seoul, South Korea.
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea.
Clin Radiol. 2021 Jul;76(7):550.e19-550.e28. doi: 10.1016/j.crad.2021.02.023. Epub 2021 Mar 22.
To investigate the prognostic significance of bone marrow (BM) 2-[F]-fluoro-2-deoxy-d-glucose (FDG) uptake in relation to posterior iliac crest BM biopsy (BMB) results in diffuse large B-cell lymphoma (DLBCL).
Pretreatment integrated positron-emission tomography(PET)/computed tomography (CT) images of 512 DLBCL patients who underwent BMB and received rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy were analysed retrospectively. BM uptake was assessed visually and by maximum standard uptake value (SUVmax). Associations with lymphoma-specific survival (LSS) were assessed using Kaplan-Meier and Cox regression analyses.
FDG(+) BM was observed in 64 cases (41 focal, 12 heterogeneous, 11 diffuse). This finding distinguished iliac crest involvement (positive in 59 and negative in 453) with 89.6% accuracy (459/512) and 93.6% specificity (424/453). In BMB(+) patients, BM-to-liver SUVmax ratio >1.8 concurred perfectly with FDG(+) BM. During 52 months of follow-up, there were 156 lymphoma-related deaths. In the entire population, multivariate analysis revealed high International Prognostic Index (IPI; p<0.001), old age (p=0.003), bulky disease (p=0.011), BMB(+) (p=0.028), and FDG(+) BM (p=0.019) as independent predictors of worse LSS. In the BMB(+) subgroup, high National Comprehensive Cancer Network-revised IPI (NCCN-IPI; p=0.029) and FDG(+) BM (p=0.008) were significant independent predictors. Among BMB(+) patients with low to low-intermediate NCCN-IPI, FDG(+) BM was associated with significantly worse 2-year LSS (33.3% versus 100%; p=0.017). The same was true among those with high-intermediate NCCN-IPI (34.7% versus 76.9%.; p=0.026).
Increased BM FDG in DLBCL is a predictor of worse LSS independent of BMB results and other prognostic variables including IPI/NCCN-IPI.
探讨弥漫性大 B 细胞淋巴瘤(DLBCL)骨髓 2-[F]-氟-2-脱氧-D-葡萄糖(FDG)摄取与髂后嵴骨髓活检(BMB)结果的关系及其预后意义。
回顾性分析 512 例接受 BMB 和利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)化疗的 DLBCL 患者的预处理整合正电子发射断层扫描(PET)/计算机断层扫描(CT)图像。通过目测和最大标准摄取值(SUVmax)评估骨髓摄取。采用 Kaplan-Meier 和 Cox 回归分析评估与淋巴瘤特异性生存(LSS)的相关性。
64 例(41 例局灶性、12 例异质性、11 例弥漫性)患者出现 FDG(+)骨髓。该发现以 89.6%(459/512)的准确率和 93.6%(424/453)的特异性区分了髂嵴受累(阳性 59 例,阴性 453 例)。在 BMB(+)患者中,骨髓与肝脏 SUVmax 比值>1.8 与 FDG(+)骨髓完全一致。在 52 个月的随访期间,共有 156 例与淋巴瘤相关的死亡。在整个队列中,多变量分析显示国际预后指数(IPI;p<0.001)高、年龄较大(p=0.003)、肿块较大(p=0.011)、BMB(+)(p=0.028)和 FDG(+)骨髓(p=0.019)是 LSS 较差的独立预测因素。在 BMB(+)亚组中,高国家综合癌症网络修订的 IPI(NCCN-IPI;p=0.029)和 FDG(+)骨髓(p=0.008)是显著的独立预测因素。在低至低-中 NCCN-IPI 的 BMB(+)患者中,FDG(+)骨髓与显著较差的 2 年 LSS 相关(33.3%对 100%;p=0.017)。在高-中 NCCN-IPI 的患者中也存在同样的情况(34.7%对 76.9%;p=0.026)。
在 DLBCL 中,骨髓 FDG 的增加是独立于 BMB 结果和包括 IPI/NCCN-IPI 在内的其他预后变量的 LSS 较差的预测因子。